Cross-source perspective and TSO verification conclusion: The three sources are highly consistent on the core deal information. All confirm that Alphabet-backed AI biotech company Isomorphic Labs closed a Series B financing round of about $210 million, led by Thrive Capital. TSO verification conclusion: the core financing facts can be cross-verified; however, the statement that the funds will be used to expand the AI drug-design platform and advance internal programs into clinical trials appears only in the event summary and cannot be directly confirmed from the three sources provided.
Confirmed facts across the sources: 1) the financing recipient is Isomorphic Labs; 2) the financing round is Series B; 3) the deal size is at the $2.1 billion level; 4) Thrive Capital is the lead investor; 5) participating investors include Alphabet/GV, Temasek, CapitalG, and the U.K. AI Fund/UK Sovereign AI Fund. Source 1 is dated May 12, 2026; Source 2 is dated May 12, 2026; Source 3 is dated May 13, 2026.
Main discrepancies or differences: There is no material conflict among the three sources regarding the core transaction, but there are minor differences in how participating investors are named. Source 1 refers to “Alphabet/GV, MGX, Temasek, CapitalG and the U.K. AI fund”; Source 3 refers to “Alphabet, Google/GV, Temasek, Capital G and the UK Sovereign AI Fund”; Source 2 only confirms that Isomorphic Labs “closed a $2.1 billion Series B round” and does not list all investors. Accordingly, whether MGX participated, and whether “U.K. AI fund” and “UK Sovereign AI Fund” refer to the same entity, cannot be further confirmed from the provided sources.
Background and analysis: Based on the sources, this financing is described by multiple media outlets as an important expansion step for Isomorphic Labs in AI drug discovery. Source 2 says the round “cement[ed] its role in AI drug discovery,” while Source 3 calls it “the second largest biotech round ever.” However, the “second largest biotech round” ranking is a media characterization; although it appears in Source 3, the ranking methodology, scope, and comparison baseline are not detailed in the provided sources and therefore cannot be independently verified. The sources also do not provide verifiable details on how the funds will be allocated or whether there is a confirmed plan to advance internal programs into clinical trials.
Three-source summary: Source 1 emphasizes the financing amount, lead investor, and participant list; Source 2 emphasizes that the transaction has closed and frames Isomorphic Labs as an important player in AI drug discovery; Source 3 emphasizes the size of the financing and its high ranking in biotech financing history while also listing participating investors. Taken together, the sources mutually reinforce the core facts, but only Source 1 and Source 3 provide relatively complete investor details.
Conclusion: Based on cross-source verification, it can be confirmed that Isomorphic Labs has completed a Series B financing round of about $210 million, led by Thrive Capital, with participation from Alphabet-related capital and several institutions. Beyond those confirmed facts, more detailed funding allocation plans, the timeline for clinical advancement, and the ranking methodology for the financing round cannot be confirmed from the provided sources.